Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Acquisitions & Divestments: 2015-2025

Historic Change in Acquisitions & Divestments for Viking Therapeutics (VKTX) over the last 10 years, with Sep 2025 value amounting to $181.5 million.

  • Viking Therapeutics' Change in Acquisitions & Divestments rose 3.18% to $181.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $786.9 million, marking a year-over-year increase of 43.14%. This contributed to the annual value of $560.0 million for FY2024, which is 87.16% up from last year.
  • Latest data reveals that Viking Therapeutics reported Change in Acquisitions & Divestments of $181.5 million as of Q3 2025, which was up 9.34% from $166.0 million recorded in Q2 2025.
  • Viking Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $295.9 million during Q1 2025, with a 5-year trough of $32.3 million in Q1 2022.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $136.8 million (2024), whereas its average is $136.6 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first tumbled by 61.85% in 2021, then skyrocketed by 163.05% in 2024.
  • Viking Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $63.0 million in 2021, then dropped by 17.65% to $51.9 million in 2022, then spiked by 156.94% to $133.3 million in 2023, then climbed by 7.71% to $143.5 million in 2024, then rose by 3.18% to $181.5 million in 2025.
  • Its Change in Acquisitions & Divestments was $181.5 million in Q3 2025, compared to $166.0 million in Q2 2025 and $295.9 million in Q1 2025.